News

Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and ...
New data from the VOLITION study reveal that 89% of treatment-naïve individuals with HIV chose to switch to long-acting cabotegravir and rilpivirine after achieving viral suppression with oral DTG/3TC ...